TY - JOUR
T1 - TGF-β and IL-17 serum levels and specific immunotherapy
AU - Ciprandi, Giorgio
AU - De Amici, Mara
AU - Negrini, Simone
AU - Marseglia, Gianluigi
AU - Tosca, Maria Angela
PY - 2009/9
Y1 - 2009/9
N2 - Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels.
AB - Two new T cell subsets may be involved in allergic rhinitis (AR) pathogenesis: Th17 and T regulatory cells, mainly producing IL-17 and TGF-β respectively. Successful Sublingual Immunotherapy (SLIT) induces relevant immunological changes, thus the aim of this study was to evaluate serum IL-17 and TGF-β levels in AR patients treated with SLIT for 2 years. Patients' blood samples were collected before initiating SLIT (baseline), three months after the end of the first pre-seasonal SLIT course, and at the end of the second pre-seasonal course. IL-17 was detectable only in the most severe allergic patients. SLIT significantly induced an increase in serum TGF-β levels. There was moreover a significant relationship between TGF-β and symptom severity and drug use at the end of the study. Therefore, this study provides clinically relevant evidence that two pre-seasonal SLIT courses may significantly affect serum TGF-β levels.
KW - Allergic rhinitis
KW - IL-17
KW - Sublingual immunotherapy
KW - TGF-β
UR - http://www.scopus.com/inward/record.url?scp=68949170682&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=68949170682&partnerID=8YFLogxK
U2 - 10.1016/j.intimp.2009.07.004
DO - 10.1016/j.intimp.2009.07.004
M3 - Article
C2 - 19622397
AN - SCOPUS:68949170682
VL - 9
SP - 1247
EP - 1249
JO - International Immunopharmacology
JF - International Immunopharmacology
SN - 1567-5769
IS - 10
ER -